Chronic HCV Infection: Clinical Advances and Eradication Perspectives - Part II

Dear Colleagues,

In 2016, the World Health Organization (WHO) proposed a plan to eradicate Hepatitis C virus (HCV) by 2030. HCV is responsible of hepatic (liver fibrosis, cirrhosis and hepatocellular carcinoma) and extra-hepatic (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, and so on) diseases. Additionally, clinical manifestations could worsen by viral co-infections, such as Hepatitis B virus (HBV), Hepatitis E virus (HEV) and Human Immunodeficiency Virus (HIV). Screening policy in the general population as well as in specific risk categories is necessary to allow for timely diagnosis and treatment. Direct-Acting Antiviral (DAA) drugs are used to cure HCV infected people independently of the genotype/subtype with high rate of sustained viral response (SVR). However, pan-genotypic regimens efficacy can be influenced by resistance-associated substitutions (RASs) carried on genomic target regions of particular HCV isolates.

This Special Issue aims to discuss HCV elimination program before and during the ongoing SARS-CoV-2 pandemic, considering the reallocation of public health resources. We would like to invite original research, short communications, review and viewpoints. We look forward to your evaluable scientific contributions.

We are delighted to announce the Part II of the Special Issue “Chronic HCV Infection: Clinical Advances and Eradication Perspectives”.

Dr. Nadia Marascio
Prof. Dr. Giovanni Matera
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.